PVP Ventures Limited has announced a major strategic pivot, proposing a name change to Evervie Health Limited to align with its new focus on cancer, renal, senior, and women’s health. While consolidated income rose to Rs 112.96 crore in FY26, the company reported a net loss of Rs 9.96 crore. Shareholders will vote on the rebranding, a new ESOP 2026 scheme involving 2 crore shares, and the appointment of new leadership during the upcoming 35th Annual General Meeting on September 7, 2026.
PVP Ventures Pivots to Healthcare Under New Name Evervie Health
Total Income: Rs 112.96 Crore (FY26) vs Rs 38.61 Crore (FY25)
Net Loss: Rs 9.96 Crore (FY26) vs Rs 8.56 Crore (FY25)
Reader Takeaway: Revenue is rising through healthcare acquisitions, but bottom-line losses persist as the company funds its strategic transformation.
What just happened
PVP Ventures has formally signaled its transition from a diversified entity to a healthcare-focused business. The company is seeking shareholder approval at its 35th Annual General Meeting on September 7, 2026, to change its corporate identity to 'Evervie Health Limited.' To support this shift, the company is introducing the 'PVP ESOP Scheme 2026,' allowing for the issuance of up to 2 crore equity shares to staff and directors.
Why this matters
The strategic move follows the acquisition of majority stakes in Biohygea Global, Optimus Oncology, and 7Med India. Management has defined four key operational pillars: Cancer Care, Renal Care, Senior Care, and Women’s Health. This restructuring represents a fundamental change in business model, moving away from legacy operations toward specialized healthcare services.
Financial Context
Despite a significant jump in total income—up from Rs 38.61 crore to Rs 112.96 crore—the company has yet to turn a profit. The consolidated net loss widened slightly to Rs 9.96 crore from Rs 8.56 crore in the previous fiscal year. Management has cited ongoing investments in the new healthcare platform as the primary driver for these costs.
Risks to watch
Investors should note the company's report of 'inadequate profits,' which has triggered the need for special resolutions to approve managerial remuneration for Chairman Prasad V. Potluri. Additionally, the Secretarial Audit Report flagged historical compliance issues, including delayed financial filings and quorum lapses, though the company confirms fines were addressed.
What to track next
The ultimate test for shareholders will be the integration of the three recently acquired subsidiaries and the conversion of the current high-revenue, loss-making model into a sustainable, profitable healthcare operation. Monitor the execution of these four medical verticals in upcoming quarterly reports.